From a biomarker perspective, further studies should investigate whether quantitative assessment of intratumoral Th1 and Th2 cells by multiplex IHC could complement the CD3/CD8-based Immunoscore, which is already clinically validated for prognostication in stages II to III colorectal cancer and is under prospective evaluation in clinical trials (49, 50). Here, CD8A is linked to colorectal cancer.